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PROCEEDINGS OF THE NUTRITION SOCIETY 
A Scientific Meeting was held at the University of Leeds on 21-22 November 1991 
The Sir David Cuthbertson 
Medal Lecture 1991 
The mechanisms and treatment of weight loss in cancer 
B Y  K E N N E T H  C .  H .  F E A R O N  
University Department of Surgery, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh 
EH3 9YW 
It is always a very great pleasure when one meets an individual whose work has been of 
considerable scientific importance. I was honoured to have met Sir David Cuthbertson 
on several occasions towards the end of his life and, thus, it gives me particular pleasure 
to be invited by the Clinical Metabolism and Nutritional Support Group of the Nutrition 
Society to give this lecture in his memory. Sir David was particularly interested by the 
metabolic response to trauma and in this lecture I wish to dwell on another part of the 
spectrum of the response to injury in terms of the metabolic disturbance in patients with 
cancer. 
It goes without saying that the majority of patients with cancer will eventually lose 
weight and a proportion become emaciated to the extent that they appear to die of 
starvation. This syndrome is known as cancer cachexia, the term cachexia being derived 
from the Greek words ‘kaxos’ and ‘hexis’ meaning poor condition. The patient with 
cachexia is characterized by a group of symptoms including anorexia, early satiety, 
marked weight loss, aesthenia, anaemia and oedema. The importance of weight loss in 
cancer has long been recognized. As far back as 1932 Warren in a post-mortem study 
estimated that as many as 22% of patients with cancer die primarily as a result of 
cachexia (Warren, 1932). More modern studies would put this percentage at perhaps 10 
(Inagaki et al. 1974). Nevertheless, currently the majority of cancer patients die from 
sepsis, and there remains the complex inter-relationship between poor nutritional status 
and a propensity to infection. 
Unfortunately, for the majority of patients whose cancer has spread beyond the organ 
of origin, neither surgery, radiotherapy or chemotherapy is able to offer a cure. With the 
recognition of the morbidity and mortality associated with cachexia, the past 15 years 
have seen attempts to use nutritional support to try to reverse the nutritional deficit 
associated with progressive cancer growth. These studies have, however, not met with 
great success. Conventional nutritional support does not readily reverse the nutritional 
deficits associated with progressive tumour growth (Nixon et al. 1981; Cohn et al. 1982) 
and not surprisingly nutritional support has failed to reduce overall morbidity and 
mortality (Brennan, 1981; Chlebowski, 1986). These disappointing results have led 
investigators back to the drawing board to try to understand the fundamental reasons for 
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Fig. 1. Body composition of a group of lung cancer patients (n 6) who had lost 30% of their pre-illness stable 
weight compared with a group of controls matched for age, sex, height and pre-illness stable weight of the 
cancer patients. NS, not significant; LBM, lean body mass. 
weight loss to see if we can design specific forms of nutritional support or metabolic 
intervention which might influence more favourably the host-tumour relationship. 
CHANGES IN BODY COMPOSITION ASSOCIATED WITH CANCER CACHEXIA 
In order to understand the mechanisms of weight loss in cancer, perhaps the first step 
should be to try to quantify the nature and extent of tissue loss. Fig. 1 shows the results of 
a study undertaken by us on a group of lung cancer patients who had lost 30% of their 
pre-illness stable weight (Preston et al. 1987). The body composition of these patients 
was compared with a group who were matched for the age, sex, height and pre-illness 
stable weight of the. cancer patients. In the study, body protein was divided into 
non-muscle and muscle compartments using analysis based on fixed nitr0gen:potassium 
ratios as advocated by Burkinshaw et al. (1978). The most dramatic change in body 
composition was an 85% fall in total body fat. Clearly this reflects a prolonged, severe, 
negative energy balance. Second, there was marked skeletal muscle wasting with a 75% 
fall in skeletal muscle protein mass. This certainly reflects the clinical condition of these 
patients and predicts their mode of death from immobility and hypostatic pneumonia. 
Interestingly, the non-muscle protein compartment was relatively preserved and this 
would differentiate cancer cachexia from simple starvation. Several mechanisms have 
been proposed to account for preservation of the visceral protein compartment in cancer 
cachexia. First, the mass of the tumour might contribute but since human tumours rarely 
achieve a size greater than 1 kg, this seems unlikely. Second, it has been proposed that 
the tumour might produce factors which stimulate protein production by the visceral 
compartment, a concept I will return to later. 
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Table 1. Causes of reduced food intake in cancer patients 
~~~~ 
Tumour obstructing gastrointestinal tract 
Radiotherapykhemotherapy-induced nausea and vomiting 
Altered taste sensitivity 
Depression, stress, anxiety 
Oral ulceration or infection 
Learned food aversion 
Atrophy of the gastrointestinal tract 
Altered host metabolism, e.g. lactic acidosis, hypercalcaemia 
General debility/weakness 
Tumour products 
R O L E  OF A N O R E X I A  
Having documented such large negative energy and N deficits how could these have 
arisen? In terms of energy, a negative energy balance could arise as a result of a rise in 
energy expenditure, a fall in the energy intake or a combination of the two. The 
measurement of food intake in human studies is notoriously difficult. However, 
accepting these limitations it was documented (using a 24 h dietary recall technique) that 
when compared with predicted values, the food intake of the cachectic cancer patients 
whose body composition had been studied was markedly reduced both in terms of energy 
(52% reduction) and protein (25% reduction). It is well recognized that there are 
numerous factors which may contribute to anorexia in cancer patients and the list shown 
in Table 1 is by no means exhaustive. From our food intake study it is clear that anorexia 
can contribute significantly to continuing weight loss. However, the problem is that these 
patients were already cachectic when studied and, therefore, it is not clear whether the 
anorexia was giving rise to the cachexia or vice versa. In order to resolve this conundrum, 
various investigators have looked at food intake during the early phase of weight loss 
(Costa et al. 1981) but due to the difficulties of accurate documentation and substantial 
inter-individual variation, no clear answer has been achieved. This has led investigators 
to concentrate on the question of whether a rise in energy expenditure contributes to the 
negative energy balance of patients and, thus, the considerably important area of 
anorexia has been left largely unexplored. 
R O L E  OF A B N O R M A L  P R O T E I N  METABOLISM I N  H Y P E R M E T A B O L I S M  
Returning to the question of hypermetabolism, we have been particularly interested in 
the hypothesis that the rate at which protein turns over in the body is increased and that 
the energy cost of this might lead to a rise in resting energy expenditure and account for 
accelerated weight loss. Previous investigators have used a variety of labels and tracers to 
study whole-body protein kinetics and results have been variable. Some have shown no 
increase (Emery et al. 1984a; Glass et al. 1983) whilst others have found a marked 
increase (Heber et al. 1982; Eden et al. 1984; Jeevanandam et al. 1984). We, therefore, 
decided to look at a large homogeneous group of patients with colon cancer (Fearon 
et al. 198%). We determined N kinetics using a primed constant infusion of [lSN]glycine 
with tracer flux estimated from 15N enrichment in urea and ammonia at the end of the 
24 h infusion period. Rates for protein synthesis and degradation were derived 
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Fig. 2. Whole-body protein turnover (WBPT) measured with a primed, constant 24 h infusion of [15N]glycine in 
a group of patients with colorectal cancer (U; n 38) and in a group of healthy controls (a; n 8). 
using a stochastic model and the results for thirty-eight patients and eight healthy 
controls are shown in Fig. 2. It is clear that within the cancer population there is a 
substantial number of patients who appear to be normal, but equally there is a group who 
appear to have a greatly elevated rate of whole-body protein turnover. However, in 
terms of the influence of protein turnover on energy expenditure there was no 
correlation between these two variables. A lack of correlation could be due to the energy 
cost of whole-body protein turnover forming such a small component of resting energy 
expenditure that with substantial inter-individual variation any relationship between 
these two variables is lost. Alternatively, it may be that the energy costs of such elevated 
flux is significant but that other metabolic processes are changed and, thus, energy 
homeostasis is maintained. Finally, it may be that the elevated rate of tracer flux does not 
truly reflect the rate of protein turnover in the whole body and that some compartment- 
ation of the tracer may be elevating the derived rate of protein turnover. These questions 
still have to be resolved. Nevertheless, that this protein kinetic measurement reflects the 
biology of the patient is indicated by the observation that whole-body protein synthesis 
increased in a stepwise manner with anatomical stage of disease (Fig. 3). 
HEPATIC PROTEIN METABOLISM 
With such difficulty in interpreting the results of whole-body tracer flux studies, we 
decided to look at rates of protein synthesis in individual tissues of the body. It has been 
suggested that the liver might be one of the principal sites at which protein metabolism is 
altered in the cancer host (Eden et al. 1984). Liver protein synthesis is thought to be 
divided roughly 50:50 between structural and export proteins. In patients with advanced 
cancer, production of certain export proteins can be increased, e.g. the acute-phase 
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Fig. 3. Rates of whole-body protein synthesis (WBPS) measured with a primed, constant 24 h infusion of 
[*SN]glycine in a group of patients with colorectal cancer (n 38) and in a group of healthy controls. Patients 
were staged at laparotomy according to Duke’s classification (B, spread through bowel wall; C, spread to 
lymph nodes; D, hepatic metastasis). Values are means with their standard errors represented by vertical bars. 
Mean values were significantly different from those of healthy controls: *P<0.05. 
proteins (Cooper & Stone, 1979; Raynes & Cooper, 1983); however, little is known 
about hepatic structural protein synthesis. Clearly, the protein mass in an organ is 
determined by the balance between protein synthesis and degradation. We became 
particularly interested in the structural (non-export) component of liver protein synthesis 
with the observation that the organ volume of the liver and other viscera may increase in 
cancer cachexia (as opposed to a decrease observed in simple starvation (Heymsfield & 
McManus, 1985)); the obvious question being, could increased synthesis of hepatic 
non-export proteins contribute to our observed increase in whole-body protein kinetics? 
We, therefore, attempted to measure fixed hepatic protein synthesis using a primed, 
constant infusion of [15N]glycine, but coordinated the start of laparotomy with the end of 
the infusion and at this point obtained a liver biopsy (Fearon et al. 1991b). The fractional 
synthetic rate in the liver was calculated by dividing the amount of [15N]glycine 
incorporated into tissue protein per unit time, by the 15N enrichment of free glycine 
obtained from a protein-free homogenate of liver tissue. Six patients undergoing elective 
cholecystecomy and six patients with colorectal cancer and hepatic metastases were 
investigated. The patients with cancer had lost approximately 10% of their pre-illness 
stable weight. 
In the advanced cancer patients we confirmed the presence of an elevated rate of 
whole-body tracer flux but rather surprisingly the non-export hepatic protein synthesis 
fractional synthetic rate was depressed by about 30%. This draws an interesting parallel 
between cancer and sepsis where structural liver protein synthesis is also thought to be 
depressed and goes back to the concept that cancer falls somewhere in the spectrum 
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Table 2. Summary of changes (%) in tissue protein synthesis rates (skeletal muscle and 
liver) and energy expenditure in three different murine models of cancer cachexia 
Protein synthesis* 
Tumour model Muscle Liver Energy expenditure 
1. XKl hypernephroma (Emery et al. 19846) I (70) I (40) t (40)t 
T (40) 2. Ehrlich ascites (Pain et al. 1984) - - 
t (23) 3. MAC-I6 (Plumb et al. 19911) 
 
- - 
* Measured by flooding [3H]phenylalanine method. 
t Brooks et al. (1981). 
between simple starvation and trauma or sepsis (Brennan, 1977). However, to return to 
our original questions, it would appear that any potential increase in hepatic volume 
must be due to a reduction in protein degradation rather than an increase in protein 
synthesis. Furthermore, non-export hepatic protein synthesis cannot be contributing to 
the observed increase in the rate of whole-body tracer flux. There must be another 
explanation for this. 
A N I M A L  M O D E L S  OF C A N C E R  C A C H E X I A  
While we had been studying these changes in humans a new animal model of cancer 
cachexia became available; namely, a chemically-induced adenocarcinoma of colon 
grown subcutaneously in NMRI mice. This model reflects the metabolic component of 
weight loss in cancer since there is a progressive loss of body-weight yet food intake 
remains constant. During the period of weight loss tumour volume remains less than 5% 
of the animal’s total body-weight and, thus, it seems an appropriate model of human 
cancer cachexia. We have investigated this model using indirect calorimetry to measure 
total energy expenditure and an intravenous flooding dose of tritiated phenylalanine to 
measure rates of protein synthesis in the tissues (Plumb et al. 1991). 
The results from three murine models of cancer cachexia (including the MAC-16 
model) are summarized in Table 2. Rather uniquely, in each model similar methods have 
been used to investigate tissue protein synthesis rates (flooding-dose method) and energy 
metabolism (indirect calorimetry). Brooks et al. (1981) using a human XK1 hyper- 
nephroma grown in thymectomizedirradiated mice demonstrated a 40% increase in 
resting energy expenditure. However, Emery et al. (1984b) using the same tumour 
showed a marked reduction in protein synthesis both in skeletal muscle and liver. 
Clearly, the energy cost of protein synthesis in this model is not the cause of 
hypennetabolism. In contrast, Pain et al. (1984) have shown no change in muscle but an 
increase in liver protein synthesis in mice bearing the Ehrlich ascites tumour, a 
dramatically different pattern of change. Energy expenditure was not measured. With 
our own studies using the MAC-16 tumour (Plumb et al. 1991) we were not able to show 
any alteration in skeletal muscle or liver protein synthesis rates. However, energy 
expenditure was grossly elevated. It, therefore, becomes apparent that the alterations in 
energy and tissue protein metabolism which different tumours induce can vary markedly. 
This is a very important point to appreciate, particularly when trying to interpret the 
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Fig. 4. Pathways by which a tumour may influence host metabolism. 
myriad results which have been obtained in human studies. Many investigators have 
looked at small patient groups containing different types of tumour and not surprisingly 
results have been quite contradictory. 
MEDIATORS OF METABOLIC CHANGES 
Having considered the protein and energy metabolism of cancer patients it would be 
relevant to discuss what might account for the changes, whether they have prognostic 
significance and whether there are potential methods of correcting such abnormalities of 
metabolism? When considering how a tumour might influence the host, one has to 
account for the heterogeneity of the response to cancer. Some patients will remain 
weight-stable, and some will become profoundly cachectic. For those who lose weight 
this may be via a series of metabolic changes, through the development of anorexia, or 
via a combination of the two. Furthermore, there is tremendous heterogeneity in the 
metabolic response which a host may demonstrate and a whole variety of causes of 
reduced food intake. In fact, one might almost despair at trying to find one common final 
pathway to account for all these changes. Nevertheless, I think such heterogeneity gives 
us a clue. It suggests that for different tumours and even for patients with the same 
tumour we may be looking at entirely different mechanisms of weight loss. The point 
may seem obvious but it has been forgotten frequently in the past. 
Trying to develop this theme further, at present it is clear that there are three potential 
pathways whereby a tumour can influence host metabolism (Fig. 4). For the past 50 years 
people have been searching for a tumour-specific product which might influence the 
metabolism of host cells. However, although neuroendocrine tumours are well known to 
produce hormones which have a profound effect on host metabolism, no cachexia- 
inducing tumour-product has been consistently isolated from human tumours. 
The second pathway which might allow a tumour to alter host metabolism would be if 
the tumour activated the classical neuroendocrine response which so interested Sir David 
Cuthbertson. I think this area is worthy of much further study and in our own laboratory 
we have observed marked changes in the insulin:cortisol ratio which would favour the 
catabolism of host tissues (Selberg et al. 1990). However, one problem with this area is 
that it is very difficult to know whether such changes represent a primary abnormality or 
whether they may be a homeostatic response to a different change induced by the 
tumour. 
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Table 3. Results of a univariate survival analysis using Cox’s proportional hazards model 
on a group of patients with colorectal cancer (n 32) 
Statistical significance: 
Variable* X2 P 
log CRP:Alb 15.3 0~0001 
log CRP 13.3 0.0003 
Alb 10.0 04016 
Duke’s stage? 11.1 0.0039 
WBPT 4.5 0.0358 
CRP, serum C-reactive protein concentration; Alb, serum albumin concentration; WBPT, whole-body 
* Assessed at time of diagnosis and survival determined 5 years later. 
t Anatomical stage of disease. 
protein turnover measured with a primed constant 24 h infusion of [lSN]glycine. 
Finally one comes to consider the area which has seen tremendous advances within the 
past few years, that being the role of cytokines in the metabolic changes associated with 
trauma, sepsis or cancer. One reason cytokines may be important is that macrophages 
and lymphocytes (some of the principal cell types to produce cytokines), are open to a 
whole variety of influences which might change the amount and type of cytokine 
produced in response to a given tumour antigen or tumour-induced inflammatory 
response. Thus, the cytokine cascade may well provide within the same tumour type 
some of the heterogeneity to which I have repeatedly referred. 
T H E  A C U T E - P H A S E  P R O T E I N  R E S P O N S E  I N  C A N C E R  
What evidence is there that cytokines are produced in the cancer host and are of 
importance in determining metabolic change? One of the principal changes that 
cytokines bring about is a redirecting of body protein metabolism away from peripheral 
tissues (e.g. skeletal muscle) and towards the liver with the production of acute-phase 
reactants. These proteins are thought to play a key role in body defences and in the 
restoration of homeostasis following injury. It has long been recognized that with tumour 
progression an acute-phase response may develop (Cooper & Stone, 1979). However, it 
would be important to state that not all patients with metastatic disease have an 
acute-phase response and neither do all patients with weight loss. The importance of this 
phenomenon is not that it is the single most important cause of weight loss but that it may 
be a significant contributor to net of catabolism of peripheral tissues in at least a 
proportion of individuals. 
That the acute-phase response carries biological significance is suggested by our 
retrospective analysis of thirty-two of the colon cancer patients whose whole-body 
protein turnover we had studied some 5 years previously (Fearon et al. 1 9 9 1 ~ ) .  By far 
and away the strongest predictor of shortened survival was the degree of acute-phase 
response at the time of diagnosis (Table 3). Moreover, this was a much stronger 
predictor than advanced anatomical stage of disease or the presence of an elevated rate 
of whole-body protein turnover. 
Further evidence to support the significance of the acute-phase response comes from 
our recent study of the body cell mass (measured by total body K analysis) in patients 
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with weight loss and oesophagogastric cancer. In this disease patients lose weight 
principally through a reduction in food intake. However, from Fig. 5 it can be seen that 
for equivalent degrees of weight loss (27 (sE 3) v. 24 (sE 5)%;  not significant), patients 
with an acute-phase response had lost 20% of their predicted body cell mass, whereas 
patients with no acute-phase response had lost only 10%. Thus, in weight-losing cancer 
patients the presence of an acute-phase response is associated with accelerated loss of the 
vital body cell mass. Of course, it remains to be seen whether there is a cause and effect 
relationship between the acute-phase response and our observations on patients’ body 
composition or duration of survival. 
T H E  R O L E  O F  CYTOKINES I N  CANCER C A C H E X I A  
The next question to consider is which cytokines give rise to the acute-phase response in 
cancer? Cytokines such as interleukin-1 (IL-1; Dinarello, 1984), interleukin-6 (IL-6; 
Gauldie et al. 1987) and tuniour necrosis factor (TNF) (Warren et al. 1987) have been 
shown both in vitro and in vivo to elicit acute-phase protein production. In the patients 
with colon cancer whose liver protein metabolism has been studied (Fearon et al. 1991a), 
there was a strong acute-phase protein response as documented by a mean C-reactive 
protein concentration of 75 mg/l (Table 4). There has been much interest in the role of 
TNF in cancer cachexia (Balkwill et al. 1987; Sherry et al. 1989; Langstein et al. 1991) and 
previously it has been demonstrated that infusion of TNF into cancer patients can 
markedly increase serum C-reactive protein concentration (Selby et al. 1987). However, 
in the present study it was possible to detect circulating TNF in only three of six patients 
(and in those individuals in whom it was detected it was only observed at very low 
concentrations). IL-1 could not be detected in patients’ serum. In contrast, levels of IL-6 
were markedly increased (Table 4). 
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Table 4. Acute-phase and serum cytokine concentrations of a group of weight-losing 
patients with advanced colorectal cancer compared with a group of weight-stable controls 
(Mean values with their standard errors) 
CRP IL-6 
(mgfl) ( P W  
TNF IL-1 
Mean SE Mean SE (>12pg/ml) (>20pg/ml) 
Controls (n  6) 9 1 12 1 016 016 
Cancer ( n  6) 15* 19 121** 39 3/6t 016 
CRP. C-reactive protein; IL-6, interleukin-6; TNF, turnour necrosis factor; IL-1, interleukin-1. 
Mean values were significantly different from those of controls (Mann-Whitney U test): *P<0.05, **P<O.O1. 
t Range 15-22 pg/ml. 
Elevated IL-6 has also been noted in a variety of tumour-bearing mice (McIntosh et al. 
1989). It is known that IL-6 is one of the main factors controlling hepatic acute-phase 
protein production in human hepatocytes (Gauldie et al. 1987) and, therefore, it is an 
attractive hypothesis that the acute-phase response in cancer is elicited by IL-6. This 
observation does not, however, rule out the possibility of localized cytokine production 
within the liver and either TNF or IL-1 (both of which are capable of inducing the 
production of IL-6) may be of major significance. Interestingly, it has been shown that 
administration of recombinant TNF to tumour-bearing mice leads to enhanced IL-6 
production compared with controls (McIntosh et al. 1989). Thus, cytokines such as TNF 
may still have a key role in inducing the acute-phase response indirectly via an 
upregulated IL-6 response. However, in other studies, although anti-TNF antibodies 
administered to cachectic tumour-bearing mice have been shown to reduce anorexia and 
some aspects of tissue wasting, there was no change in the acute-phase response (Sherry 
et al. 1989). Such findings bring into question again the role of circulating TNF as a direct 
inducer of the acute-phase proteins in cancer but give force to the argument that TNF 
contributes in some part to cachexia independent of this mechanism. 
C O N T R O L  OF C Y T O K I N E  P R O D U C T I O N  
Lastly, in relation to the acute-phase proteins, I want to consider why some cancer 
patients develop this response whilst others do not. Clearly, the production of cytokines 
could be the result of stimulation by a tumour-specific antigen or may simply be the result 
of a non-specific inflammatory response as a result of tissue destruction. However, 
further variability might be introduced depending on the ability of the patient’s immune 
system to respond to such stimuli. I have already mentioned the studies by McIntosh 
et al. (1989) showing enhanced IL-6 production by tumour-bearing mice in response to 
exogenous TNF. We now have preliminary evidence that when cancer patients’ isolated 
peripheral blood mononuclear cells are exposed to endotoxin (another potent stimulus 
for cytokine production) the more immunosuppressed the patient, as measured by 
response to the mitogen phytohaemagglutinin, the greater the release of TNF (Gough 
et al. 1992). It is known that lymphocytes can release cytokines (e.g. interleukin-4) which 
can down-regulate monocyte production of IL-6 and TNF (te Velde et al. 1990). Thus, 
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one explanation for our results is that poor lymphocyte function in the cancer patient 
may be responsible for the increased release of cytokines. Such inter-individual 
variability in cytokine production may, thus, contribute to the variable development of 
an acute-phase response. Furthermore, if this mechanism is important, then improve- 
ment of lymphocyte function might provide a method of dampening the production of 
cytokines in these patients and, thereby, reducing the level of the acute-phase response. 
Thus, immunoregulation by nutritional or pharmacological means may be an appropriate 
mode of therapy for the cachectic cancer patient. 
TUMOUR ENERGY METABOLISM AS A TARGET FOR ANTI-NEOPLASTIC 
THERAPY 
So far I have concentrated on the nutritional consequences of progressive tumour growth 
but it is important, when considering nutritional aspects of the host-tumour relationship, 
not to forget the specific nutritional requirements of the tumour. With knowledge of 
these requirements it might be possible to develop a selective and, therefore, non-toxic 
method of reducing tumour growth rate. It goes without saying that the best way to cure 
cachexia is to cure the cancer! 
It was as far back as the 1930s that Warburg (1930) first drew attention to the energy 
metabolism of tumour cells. With his initial experiments he concluded that in tumours 
glycolysis is accelerated and is not suppressed in the presence of oxygen. He suggested 
that respiration was always disturbed in malignant cells and went further to suggest that 
disturbed energy metabolism was the actual reason for neoplastic transformation 
(Warburg, 1930). This last part of his hypothesis was certainly not the case. Nonetheless, 
further investigation has gone on to document a variety of abnormalities in numerous cell 
lines. In particular, Pederson (1978) has shown that the mitochondria of different 
tumours have a very wide spectrum of abnormality, including changes in morphology, 
enzyme content and function. This group has also shown that although glycolysis may be 
accelerated in certain poorly differentiated tumours, the majority of ATP generation 
comes from oxidative phosphorylation (Nakashima et af. 1984). 
PHARMACOLOGICAL MANIPULATION OF TUMOUR GROWTH 
Previous investigators who have attempted to use tumour energy metabolism as a target 
for selective anti-neoplastic therapy have usually concentrated either on glycolysis or on 
oxidative phosphorylation. We, in contrast, have tried to manipulate both pathways 
simultaneously to try to obtain a greater degree of selectivity. In terms of inhibiting 
mitochondrial function, we have been particularly interested in the group of compounds 
known as the rodamine dyes. Rodamine-6G is a lypophilic, fluorescent, positively- 
charged dye, which is known to accumulate in the mitochondria of living cells and has 
been shown to inhibit oxidative phosphorylation (Gear, 1974). The rodamine dyes are of 
particular interest in anti-cancer therapy because they have been shown to be selective in 
their inhibition of mitochondrial function when transformed and non-transformed cell 
lines have been compared in vitro (Lampidis et al. 1983). 
In terms of inhibiting glycolysis the agent most commonly used in anti-cancer therapy 
has been the glucose analogue 2-deoxy-D-glucose (Ball et af. 1957). However, a different 
approach has been adopted by inducing hypoglycaemia and thereby reducing the amount 
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of available glucose. For this 3-mercaptopicolinic acid (3MPA) which inhibits gluco- 
neogenesis by inhibiting phosphoenolpyruvate carboxykinase (EC 2.7.1.40; Di Tullio 
et al. 1974) has been used. Therefore, a combination of 3MPA and rodaminedG (R6G) 
in rats with the Walker 256 carcinosarcoma has been investigated (Fearon et al. 1987). 
Either 3MPA or R6G alone had no significant effect on tumour growth. In contrast, the 
combination reduced final tumour size by almost 50%. Such results suggest that 
simultaneous manipulation of both sources of intracellular ATP may be used to achieve a 
more selective control of tumour growth. 
DIETARY MANIPULATION OF TUMOUR GROWTH 
Ketone bodies are fat-derived energy substrates which may act to reduce gluco- 
neogenesis by inhibiting muscle protein degradation. Several tumour cell lines have been 
shown to be deficient in the mitochondria1 enzymes which allow the cell to use ketone 
bodies for energy production (Tisdale & Brennan, 1983; Fearon et al. 1985). Moreover, 
it has been suggested that the in vitro growth rate of certain tumour cell lines may be 
reduced by the presence of 3-hydroxybutyrate at a concentration which is observed in 
simple starvation (Magee et al. 1979). Thus, the induction of systemic ketosis in the 
cancer-bearing host has been suggested as a method of selectively feeding the host while 
restricting the supply of glucose to the tumour and reducing tumour growth rate 
(Conyers et al. 1979; Williams & Matthaei, 1981; Tisdale, 1982). 
The evidence which supports the hypothesis that ketone bodies reduce protein 
breakdown in skeletal muscle is controversial. The initial studies by Sherwin et al. (1975) 
suggested that the release of alanine from skeletal muscle may be reduced by ketone 
bodies, thereby accounting for N conservation in starvation. Subsequently, Pawan & 
Semple (1983) demonstrated that administration of DL-3-hydroxybutyrate to obese 
subjects on very-low-energy diets significantly reduced net protein loss and increased the 
fat:lean ratio of tissue loss. However, the latter study was criticized because the 
administration of salts of organic acids has a protein-sparing effect by reducing the need 
for ammonium ion excretion by the kidneys, and the same result can be achieved with an 
equal amount of sodium bicarbonate (Miles & Hammond, 1983). Thus, the current 
literature does not support a direct effect of ketone bodies on proteolysis (Miles et al. 
1983). This has been confirmed in a recent study of cachectic cancer patients (Fearon 
et al. 1988a), where a medium-chain-triacylglycerol diet supplemented with D-3- 
hydroxybutyrate did not significantly influence N balance or turnover when compared 
with an isoenergetic, isonitrogenous non-ketogenic diet. 
The effect of systemic ketosis on tumour growth rate is similarly controversial. In our 
own studies the growth rate of the Walker 256 tumour in rats was uninfluenced by the 
presence of systemic ketosis induced by a medium-chain-triacylglycerol diet 
(Fearon et al. 1985). In contrast, Tisdale et al. (1987) have shown that both weight loss 
and tumour weight are reduced in animals bearing the MAC-16 tumour when they are 
fed on a ketogenic diet. These contrasting results may simply reflect the different 
substrate requirements of different tumours. Alternatively, the response of host 
metabolism to the induction of ketosis may be different, depending on the tumour type 
involved. Interestingly, it has been suggested that altering the quality (increased n-3 fatty 
acids) of ingested fat rather than the quantity may be a more effective method of 
favourably altering the host-tumour relationship by dietary means (Beck et al. 1991). 
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SUMMARY 
Anorexia and a reduced food intake are probably the major cause of continuing weight 
loss in the cancer patient. In future much more attention will have to be paid to this area 
if we are to achieve an improvement in patients’ nutritional status. Energy-dependent 
metabolic cycles such as protein turnover, but including other cycles such as glucose- 
lactate cycling, probably compromise the adaption to semi-starvation and account for 
accelerated weight loss. These abnormalities may be influenced by a variety of factors 
including tumour specific products, alterations in neuroendocrine activity and mediators 
of the inflammatory response. Manipulation of cytokine production or the effects of such 
cytokines provide a new approach to the management of cancer cachexia. It is important 
not to forget that the altered energy metabolism and substrate requirements of tumour 
cells may provide a new target for effective anti-neoplastic therapy and there are a host 
of new approaches available in this area for future investigation. 
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